Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Current Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

IGC Pharma (IGC) Land & Improvements (2023 - 2024)

Historic Land & Improvements for Pharma (IGC) over the last 6 years, with Q1 2024 value amounting to $4.1 million.

Pharma's Land & Improvements changed 0.0% to $4.1 million in Q1 2024 from the same period last year, while for Mar 2024 it was $4.1 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $4.1 million for FY2024, which is 0.0% changed from last year.
Latest data reveals that Pharma reported Land & Improvements of $4.1 million as of Q1 2024, which was down 0.0% from $1.4 million recorded in Q4 2023.
Pharma's Land & Improvements' 5-year high stood at $4.1 million during Q1 2023, with a 5-year trough of $1.4 million in Q4 2023.